Dupilumab
- PDF / 169,311 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 77 Downloads / 186 Views
1 S
Bullous-pemphigoid flare : 2 case reports In a case series of 13 patients, two patients a 76-year-old man and a woman [age not stated] were described, who developed bullous-pemphigoid flare following discontinuation of dupilumab for bullous-pemphigoid. A 76-year-old man (patient 12), who had 3 months history of bullous-pemphigoid, started receiving SC dupilumab injections, 600mg initially, followed by 300mg every other week. He had also been receiving prednisone, started prior to dupilumab initiation. Prednisone was tapered as he had disease clearance after dupilumab initiation. However, unintentional discontinuation of dupilumab triggered bullous-pemphigoid flare. A woman, who had history of bullous-pemphigoid, started receiving SC dupilumab injections, 600mg initially, followed by 300mg every other week along with prednisone. She had quick disease clearance and had successfully tapered off prednisone following 12 weeks. However, disease clearance was maintained on dupilumab monotherapy, until she accidentally discontinued dupilumab therapy, which resulted in disease flare. Subsequently, dupilumab monotherapy was restarted and she cleared within a month. Abdat R, et al. Dupilumab as a novel therapy for bullous pemphigoid: A multicenter case series. Journal of the American Academy of Dermatology 83: 46-52, No. 1, Jul 803502194 2020. Available from: URL: http://doi.org/10.1016/j.jaad.2020.01.089
0114-9954/20/1822-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 19 Sep 2020 No. 1822
Data Loading...
